SCYNEXIS INC - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by SCYNEXIS, Inc. on June 18, 2014. The report details compensatory arrangements approved by the Board of Directors for the Chief Executive Officer and other named executive officers.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Board approved the following material changes to executive compensation, effective June 1, 2014:
- Salary Increases:
- Yves J. Ribeill, Ph.D. (CEO): New salary of $400,000.
- Charles F. Osborne, Jr. (CFO): New salary of $287,818.
- Eileen C. Pruette (General Counsel): New salary of $283,000.
- New Option Awards: Grants under the 2014 Equity Incentive Plan were approved for 187,052 shares (CEO), 57,420 shares (CFO), and 25,230 shares (General Counsel). These vest monthly over 48 months and are subject to stockholder approval of an increased share reserve.
- Option Amendments: Existing options (First and Second Options) were amended to lower the exercise price to $9.64 per share and extend the term to June 17, 2024. First Options were also amended to allow exercise of vested shares upon termination of service. These amendments are subject to stockholder approval.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future business performance. The primary contingency noted is that both the new option grants and the amendments to existing options are subject to stockholder approval.
Investor Verification Checklist
- Verify the outcome of the stockholder vote required to approve the increase in the 2014 Equity Incentive Plan share reserve.
- Confirm stockholder approval for the amendments to the First and Second Options, specifically the reduction in exercise price to $9.64.
- Review the total number of shares subject to the amended options held by executives (CEO: 30,829; CFO: 7,945; General Counsel: 9,803).
- Check subsequent filings for the final vesting schedule and exercise terms of the new option grants.